Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ICP-332 in non-segmental vitiligo (adaptive phase II/III, randomized double-blind placebo-controlled)
CTR20251135Phase 3Active
- Sponsor
- InnoCare Pharma
- Start
- May 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of soficitinib in Vitiligo, sponsored by InnoCare Pharma. Started May 2025; status: active.
02
Drugs
soficitinib
03
Conditions
Vitiligo
Beyond the preview
Go deeper on CTR20251135.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20251135.